I’ve had #neoadjuvant #immunotherapy for my #glioblastoma (G4, IDH WT, multiple adverse molec prog features) & tomorrow I’m heading to RPAH/Sydney Local Health District for definitive resection! Feeling good & most grateful for incred support from amazing family, friends, colleagues. Professor Georgina Long AO

Dalia has profiled 100s of primary resected tumors +/- neoadjuvant therapy and metastatic tumors, including those collected from patients on our trial, with her 12-marker panel. Exciting to test hypotheses about vitamin D activity on fibroblasts in paired human specimens.

🔥 Out now

The 2nd learning module in a 2-part series on the use of #immunotherapy in #HCC .
You'll learn about subgroup analyses and challenges of #IO for pts with HCC

Check out module 1 if you haven't already👇
ow.ly/4QFi50OU81r

Module 2 here👇
ow.ly/VLbq50OU81q

Hear how experts Jonathan Spicer MD PhD, Sara Najmeh, & Paula A. Ugalde apply the latest data with perioperative #immunotherapy to their everyday #NSCLC practice and improve outcomes in #LungCancer . Illustrative cases provide practical guidance for multimodal care bit.ly/40AkhiU

🔥off the press➡️ nature.com/articles/s4146…. Immune+clinical outcomes for the first 3 arms of the ongoing platform trial (NCT02451982) assessing novel IO combos in pts w/resectable PDAC. #PancreaticCancer Johns Hopkins Kimmel Cancer Center HopkinsHemOncFellowship Dr. Elizabeth Jaffee Nature Communications PanCAN Dr. Cathy Eng

#GUpath 🧩time!

#pathtwitter #pathresidents :
what's going here in this section from neoadjuvant radical cystectomy for pT2 urothelial ca
🤨❓🔬

Robust discussion on the rapidly evolving landscape of #neoadjuvant #Immunotherapy in #nsclc by Giannis Mountzios at the 9th @ILCN conference!

New Year. New Refresh.

If a patient with resectable NSCLC acheives a pCR after neoadjuvant chemo-IO would you give adjuvant IO ?

#lcsm
Comments?

Stratification of patients who will respond to anti-HER2 therapy. buff.ly/3CPkCUJ

The ideal balance between style, functionality, and protection with smart anti-theft features.

Alok Tewari presents interesting findings on molecular, truncal alterations (SPOP, TP53) & transcription signatures (AR, TGF-β) associated w/neoadjuvant anti-androgen therapy response in high-risk localized #prosatecancer METACURE trial. Day 3 of Prostate Cancer Foundation Coffey-Holden #PCFAcademy

German OCUM trial shows no #radiation needed for CRM-clear, non-low #rectalcancer .

N=530, cT2-3, Nany CRM >1mm, 🚫low, treated with upfront TME.

5y LR 2.9%
5y Distant Relapse 15.9%

Supports PROSPECT results. ⁦Journal of Clinical Oncology⁩ ⁦⁦OncoAlert⁩ ascopubs.org/doi/abs/10.120…

Round one of #chemotherapy nearly complete...Accord Health Group #capecitabine #oxaliplatin #capox #rectalcancer #ASCO23 Julie Krause #yocrc #LARC #CRCWebinar Fight Colorectal Cancer Bowel Cancer UK BCWcharity Dr. Cathy Eng University Hospitals Plymouth NHS Trust #neoadjuvant Let's hope it is working! Is #RT always necessary?

On 7NEWS Australia #TheLatest Professor Georgina Long AO discusses #neoadjuvant #immunotherapy & #PBAC recommendation to expand #PBS listing for pembrolizumab for use before surgery for patients with resectable stage IIIB-D melanoma.
Sydney Health Charles Perkins Centre Watch all> bit.ly/NeoadjuvantPBS

Uveal melanoma is a rare cancer arising from the eye. ONCODOC and TKCC are trialling neoadjuvant darovasertib in patients through the NADOM trial with potentially promising results! #medtwitter #oncology

9news.com.au/national/eye-c…

Open Access in June's BJS: Watch and wait after neoadjuvant treatment in rectal cancer: International Watch & Wait Database (IWWD) academic.oup.com/bjs/article/11… Bas Wijnhoven Des Winter Kjetil Søreide Malin Sund Martyn Evans Niels Kok Paul Sutton Robert Hinchliffe Young BJS

Cristian Valenzuela, MD teaching us about Adjuvant (keynote 716) and Neoadjuvant (S1801) immunotherapy for resectable melanoma #melanoma Binaytara Foundation

Can someone PLEASE EXPLAIN TO ME why we keep calling the Unicancer/Prodige 23 FOLFIRINOX for rectal cancer regimen a *TNT* approach???

It literally has 3 months of Adjuvant chemo, so by definition is NOT 'total' neoadj 😵‍💫 #WhatAmIMissing #CRCSM

ascopubs.org/doi/10.1200/JC…

Very good discussion by dr. Solange Peters in the role of neoadjuvant -adjuvant therapy in NSCLC in Athens!

⤵️Staging w/ neoadjuvant treatment in #esophagealcancer ⤴️survival ‼️
📌NCD 13594 👥
CHT or CRT ➡️🔪
Compared ⤵️Staging adenocarcinoma 11355✖️ SCC 2239
📊Results
👉downstaged by 1, 2, or 3+ stages 🔛 significantly ⤴️ OS
👉HR for 3+ stage ⤵️staging: 0.40adenocarcinoma & 0.55 SCC…

#ILCN 2nd day with an elegant discussion by Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ comparing neoadjuvant with adjuvant approaches in early stage #NSCLC :
Dangerous to compare different strategies without proper stratifications , excellent discussion of challenging points 👏👏

Several years ago, Uveal Melanoma had no effective treatment options. ONCODOC and Kinghorn Cancer are running the NADOM trial looking at neoadjuvant therapy prior to definitive treatment. An interesting Channel9 article. #MedTwitter

Trends in use of neoadjuvant chemotherapy for low-grade serous ovarian cancer: 🇺🇸 study SGO ACOG ASCO OncoAlert sciencedirect.com/science/articl…